Core Viewpoint - Sangamo Therapeutics, Inc. has announced a significant underwritten offering of common stock and warrants, aiming to raise approximately $25 million for working capital and general corporate purposes [2]. Group 1: Offering Details - The offering consists of 35,190,292 shares of common stock and pre-funded warrants to purchase 17,787,033 shares, along with warrants to purchase 52,977,325 shares [1]. - The combined offering price for each share of common stock and accompanying warrant is set at $0.4719, while the pre-funded warrant and accompanying warrant are priced at $0.4619 [1]. - The accompanying warrants have an exercise price of $0.4719 per share, becoming exercisable six months post-issuance and expiring five and a half years from the issuance date [1]. Group 2: Financial Implications - Gross proceeds from the offering are expected to be around $25 million before deducting underwriting discounts and estimated expenses [2]. - The company intends to utilize the net proceeds for working capital and general corporate purposes [2]. Group 3: Regulatory and Legal Aspects - A shelf registration statement on Form S-3 related to the offering was previously filed and declared effective by the SEC [3]. - The offering will be conducted solely through a prospectus, with a final prospectus supplement to be filed with the SEC [3]. Group 4: Company Overview - Sangamo Therapeutics focuses on genomic medicine, aiming to develop treatments for serious neurological diseases lacking adequate options [5]. - The company utilizes zinc finger epigenetic regulators and a capsid discovery platform to address neurological disorders and expand delivery methods [5].

Core Insights - Sangamo Therapeutics, Inc. is set to release its third quarter 2025 financial results on November 6, 2025, before market opening [1] - A conference call will be held at 8:30 a.m. Eastern on the same day to discuss financial results and provide business updates [1] Company Overview - Sangamo Therapeutics is focused on genomic medicine, aiming to develop treatments for serious neurological diseases lacking adequate treatment options [4] - The company utilizes zinc finger epigenetic regulators and a capsid discovery platform to potentially address neurological disorders and expand delivery methods [4] - Sangamo's pipeline includes multiple partnered programs and opportunities for further partnerships and investments [4]

Core Points - Sangamo Therapeutics, Inc. is set to release its second quarter 2025 financial results on August 7, 2025, after market close [1] - A conference call will be held at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates [1] - Participants can register for the call via a provided link and are encouraged to join 10 minutes early [2] Company Overview - Sangamo Therapeutics focuses on genomic medicine, aiming to develop treatments for serious neurological diseases lacking adequate options [4] - The company utilizes zinc finger epigenetic regulators and a capsid discovery platform to potentially address neurological disorders and expand delivery methods [4] - Sangamo's pipeline includes multiple partnered programs and opportunities for further partnerships and investments [4]